{"id":8604,"date":"2024-10-22T13:55:46","date_gmt":"2024-10-22T05:55:46","guid":{"rendered":"https:\/\/flcube.com\/?p=8604"},"modified":"2024-10-22T13:55:49","modified_gmt":"2024-10-22T05:55:49","slug":"inventisbio-acquires-immuno-oncology-assets-from-lyvgen-biopharma-in-rmb1-5-million-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8604","title":{"rendered":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal"},"content":{"rendered":"\n

InventisBio (Shanghai) Co., Ltd (SHA: 688382<\/a>), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.<\/p>\n\n\n\n

This agreement signifies a strategic move for InventisBio to bolster its portfolio with innovative immuno-oncology assets, while providing Lyvgen Biopharma with a valuable opportunity to monetize its proprietary technology. The deal underscores the growing activity in China’s biopharmaceutical sector and the increasing focus on immuno-oncology as a critical area for cancer treatment and research.<\/p>\n\n\n\n

The collaboration between InventisBio and Lyvgen Biopharma highlights the potential for synergies between companies in the development of novel therapies and the commercialization of cutting-edge medical solutions.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement…<\/p>\n","protected":false},"author":1,"featured_media":8605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[682,1494,1495],"class_list":["post-8604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-inventisbio","tag-lyvgen-biopharma","tag-sha-688382"],"yoast_head":"\nInventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8604\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8604\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-22T05:55:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-22T05:55:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"672\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal\",\"datePublished\":\"2024-10-22T05:55:46+00:00\",\"dateModified\":\"2024-10-22T05:55:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d35fb79f82349735e9ecfb6af15992e5.png\",\"keywords\":[\"InventisBio\",\"Lyvgen Biopharma\",\"SHA: 688382\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8604#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8604\",\"name\":\"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d35fb79f82349735e9ecfb6af15992e5.png\",\"datePublished\":\"2024-10-22T05:55:46+00:00\",\"dateModified\":\"2024-10-22T05:55:49+00:00\",\"description\":\"InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8604\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d35fb79f82349735e9ecfb6af15992e5.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d35fb79f82349735e9ecfb6af15992e5.png\",\"width\":1080,\"height\":672,\"caption\":\"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8604#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal - Insight, China's Pharmaceutical Industry","description":"InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8604","og_locale":"en_US","og_type":"article","og_title":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8604","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-22T05:55:46+00:00","article_modified_time":"2024-10-22T05:55:49+00:00","og_image":[{"width":1080,"height":672,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8604#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8604"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal","datePublished":"2024-10-22T05:55:46+00:00","dateModified":"2024-10-22T05:55:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8604"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=8604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","keywords":["InventisBio","Lyvgen Biopharma","SHA: 688382"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8604#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8604","url":"https:\/\/flcube.com\/?p=8604","name":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=8604#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=8604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","datePublished":"2024-10-22T05:55:46+00:00","dateModified":"2024-10-22T05:55:49+00:00","description":"InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8604#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8604"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=8604#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","width":1080,"height":672,"caption":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8604#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d35fb79f82349735e9ecfb6af15992e5.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8604"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8604\/revisions"}],"predecessor-version":[{"id":8606,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8604\/revisions\/8606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/8605"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}